Ildong Pharmaceutical stock surged at the beginning of trading on the 24th. A report indicating favorable clinical data for the oral glucagon-like peptide-1 (GLP-1) new drug appears to have attracted buying interest.
As of 9:11 a.m. that day, Ildong Pharmaceutical stock is trading at 22,050 won, up 7.04% (1,450 won) from the previous trading day in the KOSPI market.
Earlier, IV Research reported that Ildong Pharmaceutical's oral GLP-1 new drug 'ID110521156' showed 'competitive intermediate results' in single ascending dose (SAD) and multiple ascending dose (MAD) trials in domestic phase 1 clinical studies.
GLP-1 hormone lowers blood sugar and reduces appetite by increasing insulin production in the pancreas. Medications that mimic this hormone include Eli Lilly's Mounjaro and Novo Nordisk's Wegovy, both of which are obesity treatments.
IV Research noted that the data for Ildong Pharmaceutical's new drug is 'comparable to the data from Eli Lilly's Orfoglipron, which is leading the low-molecular GLP-1 field,' and noted that a top-line data announcement, including a high-dose (200 mg) dosing cohort, is scheduled for August to September of this year, drawing attention to additional weight loss effects and safety profiles.